Stock listing

NASDAQ:STRO Sutro Biopharma, Inc. Stock

Home listing (NASDAQ) of Sutro Biopharma, Inc.

Follow Sutro Biopharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:STRO

$8.60 USD +0.10 (+1.2%)

Close on Nov 20, 2026

Past year +1.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.39 – $9.08 USDNov 20, 2026
Volume
275,896 sharesNov 20, 2026
Market cap
$142.8M USDAt the close on Nov 20, 2026 · price × 16.60M shares outstanding
52-week range
$7.15 – $43.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.07M USDMedian day 256,225 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sutro Biopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:STRO · Home$8.60 USD+0.10 (+1.2%)275,896$8.58$9.08$8.39$8.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:STRO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.60+0.10+1.2%$8.58$9.08$8.39275,896
$8.50-0.42-4.7%$8.85$9.06$8.35307,217
$8.92-0.40-4.3%$9.36$9.57$8.65210,457
$9.32-0.50-5.1%$9.54$9.64$8.33260,092
$9.82+0.23+2.4%$10.09$10.29$9.08333,244
$9.59-0.67-6.5%$10.01$10.12$9.20657,285
$10.26+0.09+0.9%$10.35$10.36$9.94138,934
$10.17-0.44-4.1%$10.40$10.77$9.94217,227
$10.61+0.99+10.3%$9.85$10.77$9.317268,510
$9.62+0.42+4.6%$9.58$9.73$9.215182,655
$9.20-0.74-7.4%$9.93$9.93$8.90771,768
$9.94+0.43+4.5%$9.83$10.25$9.36158,744
$9.51+0.40+4.4%$9.20$9.836$9.025127,756
$9.11+0.01+0.1%$9.10$9.345$8.94147,922
$9.10-0.04-0.4%$9.04$9.40$8.802122,290
$9.14-0.15-1.6%$9.36$9.755$9.08260,214
$9.29+0.42+4.7%$8.69$9.305$8.46353,521
$8.87-0.015-0.2%$8.87$9.14$8.44453,236
$8.885-0.445-4.8%$9.32$9.428$8.11694,461
$9.33-0.96-9.3%$10.22$10.29$9.16430,837
$10.29-0.50-4.6%$10.69$10.93$10.00293,292
$10.79-0.75-6.5%$11.62$11.80$10.75439,854
$11.54+0.285+2.5%$11.25$11.70$11.11273,807
$11.26+0.315+2.9%$11.01$11.46$10.75345,147
$10.94-0.52-4.5%$11.47$11.47$10.59363,464
$11.46+0.94+8.9%$10.54$11.65$10.51418,381
$10.52-0.49-4.5%$10.99$11.31$10.36489,824
$11.01-2.27-17.1%$13.11$13.19$10.84406,676
$13.28-0.99-6.9%$14.08$14.21$12.83298,744
$14.27-1.05-6.9%$15.31$15.42$14.05256,225
$15.32+0.66+4.5%$14.46$16.21$14.40499,983
$14.66+0.21+1.5%$14.24$15.78$14.01232,534
$14.45-0.68-4.5%$15.14$15.47$14.37162,793
$15.13-0.22-1.4%$15.46$15.46$14.27160,397
$15.35-0.62-3.9%$16.15$16.15$14.59372,135
$15.97-0.14-0.9%$16.07$16.32$15.62196,925
$16.11+0.01+0.1%$16.22$16.66$15.85133,973
$16.10+0.07+0.4%$16.05$16.27$15.74202,398
$16.03+0.05+0.3%$15.89$16.24$15.20165,702
$15.98+0.27+1.7%$15.61$16.19$14.95292,052
$15.71-0.02-0.1%$15.68$16.00$15.15252,896
$15.73-0.40-2.5%$16.09$16.17$15.56294,016
$16.13-0.22-1.3%$16.43$16.55$16.00246,239
$16.35+1.01+6.6%$14.99$16.52$14.99320,338
$15.34-0.14-0.9%$15.58$15.58$14.81651,375
$15.48-0.12-0.8%$15.94$16.13$15.25348,384
$15.60-0.96-5.8%$16.66$16.80$15.17273,298
$16.56-0.35-2.1%$16.82$16.82$15.431,294,196
$16.91+0.05+0.3%$17.09$17.41$16.53251,661
$16.86-0.97-5.4%$18.07$18.27$16.48942,335
$17.83-0.525-2.9%$18.01$18.21$17.58169,204
$18.36-0.745-3.9%$19.01$19.46$18.24145,605
$19.10-0.97-4.8%$19.61$19.76$19.04153,539
$20.07-0.47-2.3%$20.30$20.43$19.86124,764
$20.54+0.07+0.3%$20.52$20.78$19.92158,118
$20.47-0.35-1.7%$20.82$21.28$19.84134,543
$20.82+0.58+2.9%$19.97$21.04$19.89129,483
$20.24-0.21-1.0%$20.46$20.89$19.46169,297
$20.45-0.86-4.0%$21.31$21.56$20.28143,817
$21.31-0.12-0.6%$21.42$21.68$21.0492,167
$21.43-0.010.0%$21.25$21.83$20.97214,931
$21.44+0.95+4.6%$20.75$21.82$20.75108,233
$20.49-0.55-2.6%$21.49$21.51$19.55275,915
$21.04-0.12-0.6%$21.39$21.86$20.84194,683
$21.16-0.75-3.4%$21.50$22.14$20.45154,667

Splits

1 split · NASDAQ:STRO · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:STRO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sutro Biopharma, Inc. news

Sutro Biopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 114 in all · newest Nov 12, 2026 · oldest 2019
Decks
67 decks · latest November 2026

Where Sutro Biopharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:STRO · Home listing · This pageNASDAQUnited StatesUSD
gettex:S090gettexGermanyEUR
Lang & Schwarz:A41VMFLang & SchwarzGermanyEUR
Tradegate:S090TradegateGermanyEUR
LS Exchange:A41VMFLS ExchangeGermanyEUR
BOATS:STROBOATSUnited StatesUSD
Frankfurt:S090FrankfurtGermanyEUR
Dusseldorf:S090DusseldorfGermanyEUR
Munich:S090MunichGermanyEUR

Valuation

EV/sales 5.8× against a median of 16.0×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$259.6M USD
P/E
Loss
EV/sales
5.8×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
28.3%
Operating margin
−265.0%
Net margin
−344.2%
Debt to equity
Negative equity
Beta vs S&P 500
1.14

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.74Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.0Mn/an/an/a3.7×n/a0.6×n/a
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.29Mn/a29.8×n/a1.4×n/a0.3×n/a
Protara Therapeutics, Inc. · NASDAQ:TARAUS$140.4MUS$15.77Mn/an/an/a1.0×n/a0.0×1.12
Cloudbreak Pharma, Inc. · HKEX:2592US$140.4MUS$82.03Mn/an/an/a2.3×n/a0.0×n/a
Scancell Holdings PLC · LSE:SCLPUS$140.3MUS$155.7Mn/an/an/an/an/an/an/a
Median of the othersUS$145.1MUS$65.89M16.0×1.3×−190.2%0.1×1.31

Forecasts

10 strong buy · 3 buy · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
50.42 USD · Analysts' mean
EPS, year to Dec 2026
-6.22 · 1 analyst
Revenue, year to Dec 2026
51.15M · 12 analysts

Team and board

Officers

OfficerRole
Jane ChungChief Executive Officer & Member, Board of Directors
Greg ChowChief Financial Officer
Lucas DonigianSenior Vice President, Business Development
Hans-Peter GerberChief Scientific Officer

Board

DirectorRole
Connie MatsuiChair, Board of Directors
Daniel H. PetreeMember, Board of Directors
Heidi HunterMember, Board of Directors
James PanekMember, Board of Directors
Jane ChungChief Executive Officer & Member, Board of Directors
Jon WiggintonMember, Board of Directors
Joseph M. LobackiMember, Board of Directors
Michael DybbsMember, Board of Directors
Sukhi JagpalMember, Board of Directors

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+2.4%
Q2 2026Aug 12, 2026 · Before open−14.9%
Q1 2026May 14, 2026 · After close+1.4%
Q4 2025Mar 12, 2026−6.0%
Q3 2025Nov 6, 2025 · After close−13.4%
Q2 2025Aug 7, 2025 · After close+0.3%
Q1 2025May 8, 2025 · After close−9.1%
Q4 2024Mar 24, 2025 · Before open+0.4%
Q3 2024Nov 13, 2024 · After close−12.9%
Q2 2024Aug 13, 2024 · After close+11.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+2.6%
Q4 2023Mar 25, 2024 · After close+27.8%
Q3 2023Nov 13, 2023 · After close+14.5%
Q2 2023Aug 10, 2023 · After close−1.8%
Q1 2023May 15, 2023 · Before open+4.3%
Q4 2022Mar 30, 2023 · After close+3.1%
Q3 2022Nov 8, 2022 · After close+2.7%
Q2 2022Aug 8, 2022 · After close+6.6%
Q1 2022May 9, 2022 · After close+6.0%
Q4 2021Feb 28, 2022 · After close−2.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck33 slidesNovember 2026
Investor Presentation (November 2026)Investor deck32 slidesNovember 2026
Investor Presentation (October 2026)Investor deck33 slidesOctober 2026
Investor Presentation (August 2026)Investor deck29 slidesAugust 2026
Investor Presentation (February 2026)Investor deck27 slidesFeb 10, 2026
Investor Day (November 2025)Investor day57 slidesNov 12, 2025
Investor Presentation (November 2025)Investor deck29 slidesNovember 2025
Investor Presentation (November 2025)Investor deck32 slidesNovember 2025
Investor Presentation (October 2025)Investor deck29 slidesOctober 2025
Investor Presentation (September 2025)Investor deck29 slidesSeptember 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (August 2025)Investor deck26 slidesAugust 2025
Investor Presentation (July 2025)Investor deck29 slidesJuly 2025
Investor Presentation (May 2025)Investor deck29 slidesMay 2025
Investor Presentation (May 2025)Investor deck28 slidesMay 2025
Investor Presentation (April 2025)Investor deck29 slidesApril 2025
Conference Presentation (March 2025)Conference9 slidesMarch 2025
SGO 2025 Annual Meeting on Women's CancerConference13 slidesMarch 2025
Investor Presentation (February 2025)Investor deck31 slidesFebruary 2025
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference27 slidesJanuary 2025
Jefferies London Healthcare Conference 2024Conference30 slidesNov 21, 2024
Investor Presentation (October 2024)Investor deck36 slidesOctober 2024
Investor Presentation (September 2024)Investor deck28 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck28 slidesAugust 2024
Investor Presentation (July 2024)Investor deck26 slidesJul 2, 2024
Investor Presentation (July 2024)Investor deck26 slidesJuly 2024
Investor Presentation (May 2024)Investor deck26 slidesMay 2024
Investor Presentation (April 2024)Investor deck27 slidesApril 2024
Investor Presentation (March 2024)Investor deck30 slidesMarch 2024
Investor Presentation (January 2024)Investor deck29 slidesJan 8, 2024
Luvelta Forum (January 2024)Conference38 slidesJan 4, 2024
14th Annual World ADC San Diego 2023Conference25 slidesOct 12, 2023
Technical Presentation (October 2023)Technical9 slidesOctober 2023
J.P. Morgan Healthcare Conference 2023Conference21 slidesJan 12, 2023
Technical Presentation (January 2023)Technical20 slidesJan 9, 2023
Investor Presentation (January 2023)Investor deck21 slidesJan 9, 2023
ASCO 2023Conference15 slides2023
Investor Presentation (November 2022)Investor deck31 slidesNovember 2022
2022 Wells Fargo Healthcare ConferenceConference31 slidesSep 9, 2022
Investor Presentation (June 2022)Investor deck27 slidesJun 28, 2022
JMP Securities Life Sciences Conference 2022Conference25 slidesJun 16, 2022
21st Annual Needham Virtual Healthcare Conference 2022Conference25 slidesApril 2022
Investor Presentation (January 2022)Investor deck25 slidesJan 10, 2022
Technical Presentation (January 2022)Technical15 slidesJan 5, 2022
Investor Presentation (November 2021)Investor deck25 slidesNovember 2021
Jefferies London Healthcare Conference 2021Conference25 slidesNovember 2021
Investor Presentation (September 2021)Investor deck25 slidesSeptember 2021
ASCO 2021Conference7 slidesJune 2021
Investor Presentation (June 2021)Investor deck25 slidesJune 2021
Investor Presentation (May 2021)Investor deck25 slidesMay 19, 2021
7th Annual Truist Securities Life Science Summit 2021Conference24 slidesMay 4, 2021

This page holds 50 of 67 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$110M · US$13.98 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), LifeSci Capital (co-lead)
Buyers: BVF Partners L.P.; Samsara BioCapital; Coastlands Capital; Eventide Asset Management; Perceptive Advisors; RA Capital Management; ADAR1 Capital Management; Affinity Asset Advisors; Acuta Capital Partners
Use of proceeds: General corporate purposes, including research, clinical and process development and manufacturing of product candidates, and working capital
Feb 10, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Sep 26, 2018.

Price
US$15.00 a share
Shares offered
5,667,000 shares of common stock
Offering size
US$85 million
Underwriters' option
Up to 850,050 more shares
Underwriters
Cowen, Piper Jaffray, JMP Securities, Wedbush PacGrow · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJun 1, 2018
Filed publiclyAug 29, 2018
Amended onceSep 17, 2018
Shares registered with an exchangeSep 18, 2018
Declared effective by the SECSep 26, 2018
Final prospectus, with the priceSep 27, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Sep 27, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue102.5M62.0M153.7M67.8M61.9M42.7M42.7M38.4M51.7M59.7M
Cost of revenue7.32M7.22M6.82M8.29M9.77M77.0M65.6M54.3M51.9M43.5M
Gross profit95.2M54.8M146.9M59.5M52.1M-34.2M42.7M-15.8M-156.0K16.2M
Research and development166.4M252.0M180.4M137.2M104.4M77.0M65.6M54.3M54.6M43.5M
Selling, general and administrative41.0M48.5M62.6M59.5M56.0M36.8M32.6M21.4M16.4M14.8M
Operating income-158.4M-238.5M-89.3M-128.9M-98.5M-71.1M-55.5M-37.2M-19.3M1.36M
Depreciation and amortization7.32M7.22M6.82M5.69M4.84M4.30M4.78M4.54M4.99M5.66M
EBITDA-151.0M-231.2M-82.5M-123.3M-93.7M-66.8M-50.7M-32.7M-14.3M7.03M
Interest expense38.2M31.1M1.30M2.40M2.60M2.30M1.10M1.62M612.0K0
Income before tax-191.2M-225.1M-88.6M-116.7M-105.5M-32.0M-55.7M-35.3M-19.7M1.70M
Income tax-93.0K2.36M18.2M2.50M0103.0K00087.0K
Net income-191.1M-227.5M-106.8M-119.2M-105.5M-32.1M-119.2M-35.3M-19.7M1.70M
Earnings per share, basic-22.49-29.40-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00
Earnings per share, diluted-22.49-29.40-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents58.1M190.3M69.3M47.3M30.4M206.2M4.96M125.3M22.0M11.6M
Short-term investments83.3M126.6M264.4M255.1M130.3M120.3M112.9M79.2M035.9M
Receivables3.98M8.62M36.1M7.12M12.5M5.56M6.30M2.49M1.62M577.0K
Inventory1-11.7M11
Current assets150.9M343.3M421.5M353.2M218.5M378.2M128.6M209.9M25.6M49.7M
Property, plant and equipment10.6M18.2M21.9M24.6M22.6M12.9M9.63M10.9M14.0M18.7M
Total assets173.8M387.2M470.7M406.9M341.4M394.1M156.4M223.1M40.8M69.3M
Accounts payable7.57M10.5M9.44M4.80M6.01M5.54M5.58M3.06M2.90M3.39M
Current liabilities75.1M131.9M93.7M66.5M41.7M29.6M33.0M36.4M32.0M50.2M
Long-term debt03.77M15.7M24.5M8.88M10.0M1.71M1.19M
Total debt15.7M23.2M4.06M16.3M25.1M24.5M8.88M14.7M16.3M1.19M
Total liabilities306.3M342.6M321.1M189.9M88.8M62.1M58.6M91.6M47.3M160.2M
Shareholders' equity-132.5M44.6M149.6M217.0M252.6M332.0M97.8M131.5M-109.0M-90.9M
Shares outstanding8.58M8.31M61.0M57.5M46.3M45.8M23.1M22.8M465.3K23.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-177.2M-191.5M-111.6M3.55M-81.7M-67.8M-65.0M12.7M-37.1M-13.2M
Capital spending-1.70M-3.10M-4.32M-7.86M-15.3M-7.13M-3.48M-1.56M-3.32M-4.39M
Free cash flow-178.9M-194.6M-115.9M-4.31M-97.0M-74.9M-68.5M11.1M-40.4M-17.5M
Cash from investing45.0M218.5M-3.92M-35.0M-97.3M604.0K-51.1M-80.2M32.6M9.59M
Cash from financing44.0K94.1M137.6M48.3M3.26M269.2M-4.18M170.8M14.6M177.0K
Dividends paid-463.0K-314.0K-297.0K
Share buybacks-490.0K-463.0K-7.00K-314.0K-327.0K84.4M15.1M184.0K
Change in cash-132.2M121.0M22.0M16.8M-175.7M202.0M-120.3M103.3M10.2M-3.38M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 9, 2026Big-stake noticeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Meeting outcomeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 21, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 21, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 2, 2026Other filingsSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
CORRESP · Letter to the SECMar 30, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 27, 2026Other filingsSEC
S-3 · Registration statementMar 23, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 23, 2026ResultsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 10, 2026Material contractSEC
424B5 · ProspectusFeb 10, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 17, 2025Current reportSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
8-K · Current reportDec 3, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 23, 2025Big-stake noticeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
8-K · Current reportSep 29, 2025Current reportSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedSep 12, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 30, 2025Big-stake noticeSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 10, 2025Meeting outcomeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Management or board changeSEC
S-8 · Registration statement for employee plansMay 30, 2025Offer documentSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 14, 2025Meeting noticeSEC
8-K · Current reportApr 14, 2025Management or board changeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 8, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 4, 2025Big-stake noticeSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
8-K · Current reportDec 10, 2024Current reportSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
8-K · Current reportAug 12, 2024Management or board changeSEC
4 · Change in ownershipJul 10, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
DEFA14A · Additional proxy materialMay 17, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
4 · Change in ownershipApr 12, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 5, 2024Big-stake noticeSEC
8-K · Current reportApr 2, 2024Material contractSEC
424B5 · ProspectusApr 2, 2024Offer documentSEC
8-K · Current reportApr 2, 2024Material contractSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
8-K · Current reportMar 25, 2024ResultsSEC
4/A · Change in ownership, amendedMar 22, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 22, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC

This page holds 200 of 628 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sutro Biopharma, Inc.’s releases · as of Nov 6, 2026

Common shares
16,601,411
Fully diluted
16,601,411

Fully diluted

LineSharesAs of
Common shares16,601,411Nov 6, 2026

Share count over time

CountShares
Nov 6, 202616,601,411

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Bvf Inc1.25MUS$20.2MNo changeNov 16, 2026
BlackRock1.18MUS$19M+55,541Nov 13, 2026
Affinity Asset Advisors, LLC1.15MUS$18.6M−20,000Nov 13, 2026
Vanguard1.07MUS$17.2M+63,776Nov 13, 2026
Samsara Biocapital, LLC1.06MUS$17.1MNo changeNov 16, 2026
Perceptive Advisors LLC971KUS$15.6M−334KNov 16, 2026
Kynam Capital Management, LP873KUS$14.1MNo changeNov 16, 2026
Orbimed Advisors LLC744KUS$12MNo changeNov 16, 2026
Acadian Asset Management LLC558KUS$8.98M+184KNov 9, 2026
Velan Capital Investment Management LP510KUS$8.22M−2,122Nov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Goldman Sachs497KUS$8M+348KNov 16, 2026
T. Rowe Price425KUS$6.85M+412KNov 16, 2026
Qube Research & Technologies Ltd379KUS$6.11M+273KNov 13, 2026
Geode Capital366KUS$5.9M−23,841Nov 6, 2026
Two Sigma358KUS$5.77M+156KNov 16, 2026
Woodline Partners LP350KUS$5.64M−108KNov 16, 2026
Ameriprise348KUS$5.61M+103KNov 16, 2026
State Street324KUS$5.23M+18,498Nov 12, 2026
Marshall Wace, LLP318KUS$5.12M+143KNov 13, 2026
Citadel290KUS$4.67M+188KNov 16, 2026
Merck & Co., Inc.272KUS$4.39MNo changeNov 13, 2026
ADAR1 Capital Management, LLC267KUS$4.3M−137KNov 16, 2026
Elmind Capital, LP228KUS$3.68M+196KNov 16, 2026
KVP Capital Advisors, LP227KUS$3.65MNo changeNov 16, 2026
JPMorgan226KUS$3.64M+66,213Nov 12, 2026
Balyasny Asset Management L.P.223KUS$3.59M−488KNov 16, 2026
Ra Capital Management, L.P.211KUS$3.4MNewNov 16, 2026
Fidelity171KUS$2.76M+170KNov 10, 2026
Point72 Asset Management, L.P.137KUS$2.2M−101KNov 16, 2026
UBS117KUS$1.88M−92,012Nov 16, 2026
Northern Trust115KUS$1.85M−11,202Nov 16, 2026
Seven Fleet Capital Management LP99,894US$1.61M−59,224Nov 16, 2026
Y-Intercept (Hong Kong) Ltd90,536US$1.46M+34,657Oct 16, 2026
Jacobs Levy Equity Management, Inc90,381US$1.46MNewNov 16, 2026
Renaissance Technologies87,247US$1.41M+923Nov 12, 2026
Schwab73,732US$1.19M+24,430Nov 16, 2026
Mackenzie68,513US$1.1M−26,254Nov 2, 2026
Invesco64,885US$1.05M+7,580Nov 12, 2026
BNP Paribas62,306US$1M+34,923Nov 12, 2026
Wellington58,319US$940K+47,519Nov 16, 2026
Morgan Stanley55,238US$890K+42,882Nov 13, 2026
Barclays51,098US$823K+14,144Nov 6, 2026
Susquehanna41,750US$673KNewNov 16, 2026
BNY41,369US$666KNo changeNov 5, 2026
Fisher Asset Management, LLC35,295US$569KNo changeNov 6, 2026
Nuveen34,872US$562K−133KNov 10, 2026
XTX Topco Ltd33,271US$536K−18,898Nov 16, 2026
HSBC29,853US$484K+23,619Nov 16, 2026
Squarepoint Ops LLC28,193US$454K−27,346Nov 9, 2026
Los Angeles Capital Management LLC26,706US$430KNewNov 12, 2026

This page holds 50 of 97 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Eventide Healthcare & Life Sciences Fund585KUS$19.4M−130KJun 30, 2026
Vanguard Total Stock Market Index Fund502KUS$16.7M−31,600Jun 30, 2026
iShares Russell 2000 ETF326KUS$10.8MNewJun 30, 2026
Vanguard Extended Market Index Fund177KUS$5.88M+8,145Jun 30, 2026
Fidelity Small Cap Index Fund174KUS$4.2MNewJul 31, 2026
Nuveen Quant Small Cap Equity Fund126KUS$3.05MNewJul 31, 2026
iShares Russell 2000 Value ETF98,529US$3.27MNewJun 30, 2026
Fidelity Extended Market Index Fund78,053US$2.28M+34,302May 31, 2026
Goldman Sachs Small Cap Equity Insights Fund77,195US$1.87MNewJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund66,530US$1.61MNewJul 31, 2026
Show 50 holders
HolderSharesValueChangeAs of
JPMorgan U.S. Small Company Fund60,304US$2MNewJun 30, 2026
iShares Micro-Cap ETF47,714US$1.58M+26,957Jun 30, 2026
Schwab Small-Cap Index Fund38,737US$936KNewJul 31, 2026
Vanguard Explorer Fund28,467US$688KNewJul 31, 2026
Schwab Small-Cap Equity Fund28,234US$682KNewJul 31, 2026
Fidelity Total Market Index Fund27,815US$813K+14,398May 31, 2026
Master Small Cap Index Series23,951US$795KNewJun 30, 2026
Fidelity Series Total Market Index Fund23,004US$672K+11,886May 31, 2026
Nuveen Small Cap Blend Index Fund21,156US$511KNewJul 31, 2026
Fidelity Small Cap Value Index Fund18,817US$625KNewJun 30, 2026
iShares Russell 2000 Growth ETF18,719US$621KNewJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF16,529US$400K−627Jul 31, 2026
Small Company Growth Portfolio14,128US$469KNewJun 30, 2026
Nuveen Equity Index Fund13,975US$338KNewJul 31, 2026
EQ/2000 Managed Volatility Portfolio13,899US$461KNewJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund13,476US$326KNewJul 31, 2026
LVIP JPMorgan Small Cap Core Fund13,437US$446KNewJun 30, 2026
LVIP State Street Small-Cap Index Fund11,500US$382KNewJun 30, 2026
Schwab Total Stock Market Index Fund10,500US$254KNo changeJul 31, 2026
NVIT GS Small Cap Equity Insights Fund10,345US$343KNewJun 30, 2026
Vy(R) Jpmorgan Small Cap Core Equity Portfolio8,860US$294KNewJun 30, 2026
Vanguard Balanced Index Fund8,468US$281K−868Jun 30, 2026
Small Cap Index Fund8,229US$273KNewJun 30, 2026
Global X Russell 2000 ETF7,595US$184KNewJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund7,075US$235K−1,736Jun 30, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund6,882US$228KNewJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio5,900US$196KNewJun 30, 2026
MetLife Russell 2000 Index Portfolio5,330US$177KNewJun 30, 2026
Fidelity Nasdaq Composite Index Fund5,177US$151K+581May 31, 2026
ATM Small Cap Managed Volatility Portfolio4,773US$158KNewJun 30, 2026
Small-Cap Index Portfolio4,574US$152KNewJun 30, 2026
Diversified Equity Alpha Master Portfolio4,102US$136KNewJun 30, 2026
NVIT Small Cap Index Fund3,561US$118KNewJun 30, 2026
Small Cap Index Trust3,289US$109KNewJun 30, 2026
1290 VT Micro Cap Portfolio3,173US$105K+1,693Jun 30, 2026
Ultra-Small Company Market Fund3,000US$99,600No changeJun 30, 2026
SA Multi-Managed Small Cap Portfolio2,842US$94,354NewJun 30, 2026
iShares Russell Small/Mid-Cap Index Fund2,781US$67,217NewJul 31, 2026
EQ/AB Small Cap Growth Portfolio2,690US$89,308NewJun 30, 2026
EQ/Small Company Index Portfolio2,690US$89,308NewJun 30, 2026

This page holds 50 of 93 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
BVF PARTNERS L P/IL7.60%1.25MFeb 10, 2026
Affinity Asset Advisors, LLC6.50%1.07MMar 31, 2026
BlackRock, Inc.6.40%1.07MJun 30, 2026
Srinivas Akkaraju6.40%1.06MFeb 11, 2026
Perceptive Advisors LLC5.80%971KSep 30, 2026
Coastlands Capital LP5.14%853KNov 5, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Shalini Sharp
Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past)
Director · Nov 8, 2018 – Jun 6, 2022 · Past
John G. Freund
Other companies: SI-BONE, Inc. (Director · Since at least Oct 16, 2018); Collegium Pharmaceutical, Inc. (Director · Since at least May 6, 2015); Protara Therapeutics, Inc. (Director · Oct 21, 2014 – Nov 8, 2019 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Dec 10, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Hansen Medical Inc (Director · Nov 15, 2006 – Jun 17, 2009 · Past); XenoPort Inc (Director · May 2, 2006 – Jul 5, 2016 · Past)
Director · Sep 26, 2018 – Jun 6, 2024 · Past
Daniel Janney
Other companies: Krystal Biotech, Inc. (Director · Since at least Sep 19, 2017); Allakos Inc (Director · Jul 18, 2018 – May 25, 2023 · Past); Viveve Medical, Inc. (Director · Aug 22, 2016 – Dec 31, 2018 · Past); Evofem Biosciences, Inc. (Director · Nov 19, 2014 – Jun 16, 2015 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – May 27, 2021 · Past)
Director · Sep 26, 2018 – Jun 17, 2019 · Past
Michael Jay Ross
Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Jun 15, 2022 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2019 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – May 23, 2018 · Past)
Director · Sep 26, 2018 – Sep 27, 2018 · Past
V Bryan Lawlis
Other companies: Spyre Therapeutics, Inc. (Director · Jul 13, 2018 – Jun 7, 2022 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 11, 2021 · Past); Humanigen Inc (Director · Aug 7, 2013 – Jun 18, 2014 · Past); BioMarin Pharmaceutical Inc. (Director · May 8, 2012 – May 23, 2023 · Past); Geron Corporation (Director · Mar 13, 2012 – May 21, 2025 · Past)
Director · Sep 26, 2018 – Sep 26, 2018 · Past
Michael Dybbs
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past)
Member, Board of Directors · Since at least Sep 26, 2018
Jon Marc Wigginton
Other companies: Checkmate Pharmaceuticals Inc (Director · Jan 30, 2022 – May 31, 2022 · Past); Cullinan Therapeutics, Inc. (Chief Medical Officer · Jan 7, 2021 – Jan 7, 2021 · Past); MacroGenics, Inc. (Sr VP, Clinical Dev. & CMO · Oct 9, 2013 – Feb 20, 2020 · Past)
Director · Since at least Nov 30, 2020
Joseph M. Lobacki
Other companies: Verastem, Inc. (Executive VP & CCO · Jan 3, 2018 – Jan 3, 2019 · Past); Medivation Inc (Chief Commercial Officer · Dec 8, 2014 – Jan 4, 2016 · Past); Celator Pharmaceuticals Inc (Director · Dec 18, 2013 – Jul 12, 2016 · Past)
Member, Board of Directors · Since at least Sep 26, 2018
Anne Borgman
Other companies: Curis, Inc. (Director · Since at least Oct 12, 2022); NextCure, Inc. (Director · Since at least Oct 1, 2021)
CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past
Arturo Molina
Other companies: Protagonist Therapeutics, Inc. (Chief Medical Officer · Since at least Nov 7, 2022); Forma Therapeutics Holdings Inc (Director · Jan 12, 2022 – Oct 14, 2022 · Past)
Chief Medical Officer · Sep 26, 2018 – Mar 4, 2022 · Past
All 32 people
PersonSeat
Connie Matsui
Other companies: Artelo Biosciences, Inc. (Chair · Since at least Jun 21, 2019); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – Nov 29, 2024 · Past)
Director · Since at least Jun 24, 2019
Daniel H. Petree
Other companies: Apollo Endosurgery Inc (Director · Nov 10, 2008 – Dec 29, 2016 · Past); Cypress Bioscience Inc (Director · Jan 2, 2006 – Jan 4, 2010 · Past)
Member, Board of Directors · Since at least Sep 26, 2018
Sukhi Jagpal
Other companies: Sierra Oncology Inc (Chief Financial Officer · Jul 15, 2015 – Jul 1, 2022 · Past); Novelion Therapeutics Inc (Chief Financial Officer · Jul 20, 2012 – Jul 15, 2013 · Past)
Member, Board of Directors · Since at least Aug 8, 2024
William J Newell
Other companies: Social Capital Suvretta Holdings Corp IV (Director · Sep 7, 2022 – Sep 7, 2022 · Past); Vaxcyte, Inc. (Director · Jun 11, 2020 – Dec 9, 2020 · Past)
CEO, Director · Sep 26, 2018 – Mar 5, 2025 · Past
Edward C Albini
Other companies: Paratek Pharmaceuticals Inc (V.P., Chief Financial Officer · May 9, 2006 – May 9, 2008 · Past)
CFO AND SECRETARY · Sep 26, 2018 – May 15, 2025 · Past
Gregory K Chow
Other companies: Aptose Biosciences Inc (Executive VP & CFO · Dec 21, 2018 – Jan 4, 2021 · Past)
CFO · Since at least Jun 2, 2025
Jane Chung
Other companies: Viracta Therapeutics Inc (Director · Aug 10, 2022 – Jun 20, 2024 · Past)
Chief Executive Officer & Member, Board of Directors · Since at least Aug 9, 2021
Anik ShabbirChief Technical Ops. Officer · Sep 26, 2018 – Mar 3, 2023 · Past
Barbara LeymanChief Business Officer · Since at least Jul 8, 2024
Brunilda ShtyllaChief Business Officer · Mar 1, 2023 – Aug 28, 2023 · Past
David PaulingChief Admin. Ofcr. & GC · Since at least Apr 4, 2025
Greg ChowChief Financial Officer · Since at least Jun 2, 2025
Hans-Peter GerberChief Scientific Officer · Since at least Sep 18, 2023
Heidi HunterMember, Board of Directors · Since at least Nov 19, 2021
James PanekMember, Board of Directors · Since at least Jan 7, 2020
Jon WiggintonMember, Board of Directors · Since at least Nov 4, 2026
Linda A FitzpatrickCHIEF PEOPLE & COMM. OFFICER · Sep 26, 2018 – May 1, 2025 · Past
Lucas DonigianSenior Vice President, Business Development · Since Sep 28, 2026
Nicki VasquezCHIEF PORT. STRAT & ALNCE OFCR · Aug 9, 2021 – Jan 29, 2024 · Past
Stephen WorsleyChief Business Officer · Sep 26, 2018 – Jan 29, 2019 · Past
Trevor HallamPres. Rsrch & Cf. Sctific Ofcr · Sep 26, 2019 – Apr 14, 2023 · Past
Venkatesh SrinivasanCHIEF TECH OP OFFICER · May 1, 2023 – May 1, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Sutro Biopharma, Inc.